Trade Basilea Pharma AG - BSLN CFD
What is Basilea (BSLN)?
Basilea Pharmaceutica Ltd. is a Swiss biopharmaceutical company focused on the development and commercialization of innovative therapies in the fields of oncology and infectious diseases. Established with a commitment to addressing unmet medical needs, the company engages in research and development activities aimed at advancing novel pharmaceutical compounds. Basilea's portfolio includes products targeting bacterial infections, fungal infections, and cancer, reflecting its dual therapeutic focus. The company operates through a combination of in-house research and strategic collaborations to enhance its pipeline and bring new treatments to market. Basilea is headquartered in Basel, Switzerland, and maintains a presence in various international markets. Its operations encompass drug discovery, clinical development, regulatory affairs, and commercialization efforts. The company emphasizes scientific innovation and regulatory compliance in its approach to pharmaceutical development. Basilea's contributions to healthcare include the introduction of therapies that address resistant infections and certain cancer types, supporting global medical needs.
Basilea Stock Price Today: Live Overview
The price today is shaped by current session activity, with Basilea priced at ₣55.2. It has experienced intraday variations between ₣52.7 and ₣55 alongside a daily change of +0.1825%.
FAQ: Basilea (BSLN)
What is the current price of BSLN stock?
Basilea's stock is priced at ₣55.2.
Does BSLN pay dividends?
Basilea does not pay dividends currently.
Does BSLN have a formal corporate presence or regional headquarters in the UAE?
Basilea does not have an official regional office or subsidiary in the UAE and operates via partners.
What is BSLN best known for?
Basilea is most famous for its pharmaceutical products and anti-infective drugs.
What assets are typically shown together with BSLN?
Commonly shown alongside BSLN: Coursera, Inc., Magic Software Enterprises Ltd, Unusual Machines, Inc.
Latest shares articles



